Blanchet, Matthieu; Le, Quoc-Tuan; Seidah, Nabil G. et Labonté, Patrick (2016). Statins can exert dual, concentration dependent effects on HCV entry in vitro Antiviral Research , vol. 128 . pp. 43-48. DOI: 10.1016/j.antiviral.2016.02.006.
Ce document n'est pas hébergé sur EspaceINRS.Résumé
Statins are used daily by a large and increasing number of individuals worldwide. They were initially designed as 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) inhibitors to treat patients with hypercholesterolemia. Recent studies on HCV chronically infected individuals have suggested that their use in vivo in combination with PEG-IFN and ribavirin favor the sustained viral response (SVR). Herein, we describe the effects of a set of statins on HCV entry and on HCV key entry factors in vitro. Our results suggest that all tested statins exert a proviral effect through the upregulation of LDLR. Interestingly, at higher concentration, we also provide evidence of a yet unknown competing antiviral effect of statins (except for pravastatin) through the downregulation of CLDN-1. Importantly, this work enlightens the blunt proviral effect of pravastatin at the entry step of HCV in vitro
| Type de document: | Article |
|---|---|
| Mots-clés libres: | HCV; Statins; CLDN-1; LDLR; NPC1L1; CD81; PCSK9; Lipids; Cholesterol |
| Centre: | Centre INRS-Institut Armand Frappier |
| Date de dépôt: | 09 mai 2017 20:48 |
| Dernière modification: | 04 déc. 2020 18:13 |
| URI: | https://espace.inrs.ca/id/eprint/4560 |
Gestion Actions (Identification requise)
 |
Modifier la notice |